Is lipid-lowering therapy underused by African Americans at high risk of coronary heart disease within the VA health care system?

American Journal of Public Health

Volumn 94, Issue 12, 2004, Pages 2112-2117

  Woodard, LeChauncy D ^a,d   Kressin, Nancy R ^b,c   Petersen, Laura A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN;

ADULT; AFRICAN AMERICAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; EUROPEAN AMERICAN; GOVERNMENT; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; RACE DIFFERENCE; REVIEW;

EID: 9644295919     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.94.12.2112     Document Type: Review

References (44)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas. Tex: American Heart Association; 2002.
2. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular disease in the United States: findings of the National Conference on Cardiovascular Disease Prevention. Circulation. 2000;102:3137-3147.
3. Clark LT, Emerole O. Coronary heart disease in African Americans: primary and secondary prevention. Cleve Clin J Med. 1995;62:285-292.
4. Lewis CE, Raczynski JM, Oberman A, Cutter GR. Risk factors and the natural history of coronary heart disease in blacks. Cardiovasc Clin. 1991;21:29-45.
5. Giles WH, Kittner SJ, Hebel JR, Losonczy KG, Sherwin RW. Determinants of black-white differences in the risk of cerebral infarction. Arch Intern Med. 1995;155:1319-1324.
6. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study. Ann Intern Med. 1971;74:1-12.
7. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med. 1992;152:1490-1500.
8. Wong ND, Cupples LA, Ostfield AM, Levy D, Kannel WB. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Am J Epidemiol. 1989;130:469-480.
9. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700-1707.
10. Newman WP, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study. N Engl J Med. 1986;314:138-144.
11. Aronow WS, Ahn C. Correlation of serum lipids with the presence or absence of coronary artery disease in 1,793 men and women aged >62 years. Am J Cardiol 1994;73:702-703.
12. Neaton JD, Kuller LH, Wentworth D, Borhani NO. Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration, and diastolic blood pressure among black and white males followed up for five years. Am Heart J. 1984;108:759-769.
13. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993;328:313-318.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
15. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
16. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
17. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anti-coagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
18. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341:70-76.
19. Gotto AM. Results of recent large cholesterol-lowering trials and implications for clinical management. Am J Cardiol 1997;79:1663-1666.
20. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
21. McBride P, Schrott HG, Plane MB, Underbakke G, Brown R. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med. 1998; 158:1238-1244.
22. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303-1307.
23. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation. 1998;98:851-855.
24. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 1999;14:711-717.
25. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/Progestin Replacement Study (HERS). JAMA. 1997;277:1281-1286.
26. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
27. Sprafka JM, Burke GL, Folsom AR, Hahn LP. Hypercholesterolemia prevalence, awareness, and treatment in blacks and whites: the Minnesota Heart Survey. Prev Med. 1989;18:423-432.
28. Nieto FJ, Afonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia: the Atherosclerosis Risk in Communities Study. Arch Intern Med. 1995;155:677-684.
29. Nelson K, Norris K, Mangione CM. Disparities, in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2002;162:929-935.
30. Stewart SH, Silverstein MD. Racial and ethnic disparity in blood pressure and cholesterol measurement. J Gen Intern Med. 2002;17:405-411.
31. Lemaitre RN, Furberg CD, Newman AB, et al. Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. Arch Intern Med. 1998;158:1761-1768.
32. Oddone EZ, Petersen LA, Weinberger M, Freedman J, Kressin NR. Contribution of the Veterans Health Administration in understanding racial disparities in access and utilization of health care: a spirit of inquiry. Med Care. 2002;40(suppl 1):I3-I13.
33. Kressin NR, Dark JA, Whittle J, et al. Racial differences in health-related beliefs, attitudes, and experiences of VA cardiac patients: scale development and application. Med Care. 2002;40(suppl 1):I72-I85.
34. Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of U.S. physicians. J Am Coll Cardiol. 1997;29:139-146.
35. Petersen LA, Normand SL, Leape LL, McNeil BJ. Comparison of the use of medications after acute myocardial infarction in the Veterans Health Administration and Medicare. Circulation. 2001;104:2898-2904.
36. Petersen LA, Normand SL, Daley J, McNeil BJ. Outcome of myocardial infarction in Veterans Health Administration patients as compared with Medicare patients. N Engl J Med. 2000;343:1934-1941.
37. Petersen LA, Normand SL, Druss BG, Rosenheck RA. Process of care and outcome after acute myocardial infarction for patients with mental illness in the VA healthcare system: are there disparities? Health Serv Res. 2003;38:1:41-63.
38. Demakis JG, McQueen L, Kizer KW, Feussner JR. Quality Enhancement Research Initiative (QUERI): a collaboration between research and clinical practice. Med Care. 2000;38(6 suppl 1):I17-I25.
39. Petersen LA, Wright SM, Peterson ED, Daley J. Impact of race on cardiac care and outcomes in veterans with acute myocardial infarction. Med Care. 2002;40(suppl 1):I86-I96.
40. Whittle J, Conigliaro J, Good CB, Lofgren RP. Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. N Engl J Med. 1993;329:621-627.
41. Peterson ED, Wright SM, Daley J, Thibault GE. Racial variation in cardiac procedure use and survival following acute myocardial infarction in the Department of Veterans Affairs. JAMA. 1994;271:1175-1180.
42. Mirvis DM, Burns R, Gaschen L, Cloar FT, Graney M. Variation in utilization of cardiac procedures in the Department of Veterans Affairs health care system: effect of race. J Am Coll Cardiol. 1994;24:1297-1304.
43. Kressin NR, Petersen LA. Racial differences in the use of invasive cardiovascular procedures: review of the literature and prescription for future research. Ann Intern Med. 2001;135:352-366.
44. Conigliaro J, Whittle J, Good CB, et al. Understanding racial variation in the use of coronary revascularization procedures: the role of clinical factors. Arch Intern Med. 2000;160:1329-1335.